Meeting
2024 ASCO Breakthrough
Outcome analysis of autologous stem cell transplantation in refractory and relapsed Hodgkin lymphoma: Insights from a North African single-institution study.
Presenter
Marouane Maaroufi, MD
Department of Clinical Hematology and Pediatric Oncology, 20th August 1953 Hospital, Ibn Rochd University Hospital Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Real-World Evidence/Real-World Data
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 172)
DOI
10.1200/JCO.2024.42.23_suppl.172
Abstract #
172
Poster Bd #
G3
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
Speaker: Joshua Brody, MD
Videos & Slides
2022 ASCO Annual Meeting
Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
Speaker: Pau Abrisqueta, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.
Speaker: Aung M. Tun, MBBS
Videos & Slides
2021 Genitourinary Cancers Symposium
Australia and New Zealand (ANZ) outcomes of high-dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumors (GCT) from 1999 to 2019: Multicenter registry-based study with ABMTRR.
Speaker: Elizabeth Anne Connolly, FRACP, MBChB, MRCP